NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis $32.82 +1.28 (+4.07%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Hims & Hers Health Stock (NYSE:HIMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hims & Hers Health alerts:Sign Up Key Stats Today's Range$31.51▼$33.2050-Day Range$25.41▼$68.8752-Week Range$11.20▼$72.98Volume5.82 million shsAverage Volume13.42 million shsMarket Capitalization$7.29 billionP/E Ratio75.04Dividend YieldN/APrice Target$37.23Consensus RatingHold Company OverviewHims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Read More… Remove Ads Hims & Hers Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreHIMS MarketRank™: Hims & Hers Health scored higher than 67% of companies evaluated by MarketBeat, and ranked 348th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 6 buy ratings, 7 hold ratings, and 2 sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth79.31% Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is 72.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is 72.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.65.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 20.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.57% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 12.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.57% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 12.40%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.41 News SentimentHims & Hers Health has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 32 news articles for Hims & Hers Health this week, compared to 19 articles on an average week.Search Interest284 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat Follows75 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 142% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,005,375.00 in company stock.Percentage Held by Insiders17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HIMS Stock News HeadlinesDespite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors (HIMS)Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.March 10, 2025 | marketbeat.comMarketBeat Week in Review – 03/03 - 03/07 (HIMS)Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continueMarch 8, 2025 | marketbeat.comPlease don’t die on me"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.March 14, 2025 | Porter & Company (Ad)Missed the Hims & Hers Rally? Clover Health Could Be NextAfter a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.March 5, 2025 | marketbeat.comWall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now (HIMS)See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.February 26, 2025 | marketbeat.comHims & Hers (HIMS) Investors Pulling Their Hair Out Over Pills Side-EffectsMarch 13 at 9:07 PM | markets.businessinsider.comDefiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & HersMarch 13 at 1:00 AM | globenewswire.comWhy the Market Dipped But Hims & Hers Health, Inc. (HIMS) Gained TodayMarch 13 at 12:52 AM | msn.comSee More Headlines HIMS Stock Analysis - Frequently Asked Questions How have HIMS shares performed this year? Hims & Hers Health's stock was trading at $24.18 at the beginning of 2025. Since then, HIMS shares have increased by 30.1% and is now trading at $31.4650. View the best growth stocks for 2025 here. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) released its quarterly earnings results on Monday, February, 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a trailing twelve-month return on equity of 10.97% and a net margin of 8.19%. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's top institutional investors include Vanguard Group Inc. (9.27%), Farallon Capital Management LLC (3.83%), Renaissance Technologies LLC (3.18%) and Arrowstreet Capital Limited Partnership (2.89%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Patrick Harrison Carroll, Michael Chi, Soleil Boughton, Jules A Maltz, Christopher D Payne, Oluyemi Okupe, Andrew Dudum, Christiane Pendarvis, Irene Becklund, Anja Manuel and Lynne Chou O'keefe. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hims & Hers Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings2/24/2025Today3/14/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryHealthcare Current SymbolNYSE:HIMS CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees1,046Year FoundedN/APrice Target and Rating Average Stock Price Target$37.23 High Stock Price Target$68.00 Low Stock Price Target$20.00 Potential Upside/Downside+18.3%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$0.54 Trailing P/E Ratio71.51 Forward P/E Ratio108.50 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins8.19% Pretax Margin4.16% Return on Equity10.97% Return on Assets8.29% Debt Debt-to-Equity RatioN/A Current Ratio2.14 Quick Ratio1.82 Sales & Book Value Annual Sales$1.48 billion Price / Sales4.73 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book19.54Miscellaneous Outstanding Shares222,166,000Free Float179,786,000Market Cap$6.99 billion OptionableOptionable Beta1.37 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NYSE:HIMS) was last updated on 3/14/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s new tariffs could break China’s grip on manufacturingLooming trade wars have China scrambling… Over 90% of global corporate executives said they are shutting do...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.